Nov 30, 2020 14:04 JST

Source: Eisai

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting


TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.

A total of 43 poster presentations regarding perampanel are planned, including analysis results from the phase III clinical trial (FREEDOM/Study 342), which evaluated the effectiveness and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with partial onset seizures (POS) from 12 to 74 years of age without prior treatment history. Additionally, results from the phase III clinical trial Study 311 evaluating safety and tolerability of perampanel as an adjunctive therapy in pediatric epilepsy patients with POS or primary generalized tonic clonic (PGTC) seizures from 4 to less than 12 years of age will be presented.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. In Japan and the United States, perampanel is currently approved for monotherapy and adjunctive use in the treatment of POS (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.

For more information, visit https://www.eisai.com/news/2020/pdf/enews202080pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
January 12 2021 11:37 JST
 
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
December 18 2020 12:09 JST
 
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
December 17 2020 11:47 JST
 
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
December 11 2020 09:43 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
December 04 2020 11:17 JST
 
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
November 30 2020 10:16 JST
 
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
November 27 2020 21:05 JST
 
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
November 18 2020 19:11 JST
 
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
November 18 2020 19:00 JST
 
Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
November 16 2020 09:06 JST
 
More Press release >>

Latest Press Release


More Latest Release >>